Glass House (GLAS) Q3 2026 Earnings Call Transcript

The Motley Fool · 1d ago
Logo of jester cap with thought bubble.

Image source: The Motley Fool.

DATE

Mon, Nov. 16, 2026

CALL PARTICIPANTS

  • Co-Founder, Chairman and Chief Executive Officer - Kyle Kazan
  • Chief Financial Officer - Mark Vendetti
  • Co-Founder and President - Graham Farrar

TAKEAWAYS

  • Revenue -- $56.8 million, representing an increase from $26.2 million in the prior year third quarter due to expanded cultivation capacity.
  • Wholesale Biomass Revenue -- $50 million, driven by record production volumes across the company footprint.
  • CPG Revenue -- $6.3 million, compared to $5 million in the third quarter of 2025.
  • Biomass Production -- 319,000 pounds, representing a record for the company and an increase from 246,000 pounds in the second quarter of 2026.
  • Cost of Production -- $109 per pound, reflecting a 10.7% decrease from $122 per pound in the second quarter of 2026.
  • Average Selling Price -- $151 per pound, falling from $211 per pound in the prior quarter due to an unfavorable sales mix and market price compression.
  • Trim Sales Mix -- 63% of total pounds sold, significantly higher than the company historical best of 45%.
  • Flower and Smalls Mix -- 37% of total sales, down from higher proportions in previous periods as the company worked through trim-heavy inventory.
  • Gross Profit -- $14.6 million, maintained near second quarter levels as higher production volume offset lower pricing.
  • Gross Margin -- 26%, declining from 34% in the second quarter of 2026 but improving from 21% in the prior year period.
  • Adjusted EBITDA -- $0.8 million, down from $5.7 million in the second quarter due to lower gross profit and higher professional fees related to the NYSE uplisting.
  • Operating Cash Flow -- negative $0.1 million, compared to positive $0.2 million in the second quarter of 2026.
  • Cash and Restricted Cash -- $39.7 million, including $28.1 million raised through equity issuance and warrant redemptions during the quarter.
  • Equity Financing -- $18 million in net proceeds, raised via the at-the-market facility at an average price of $8.11 per share.
  • Annual Biomass Production Guidance -- 1 million pounds, with management confirming they remain on track to reach this target for the full year.
  • Fourth Quarter Cost Guidance -- $109 per pound, expected to remain stable as operational gains offset seasonal production declines.
  • Long-Term Cost Target -- $95 per pound, which the company maintains as its primary operational goal.
  • Planned Capital Expenditures -- $20 million, focused on facility upgrades and process improvements to enhance flower yields and mix consistency.
  • Licensed Cultivation Footprint -- 2 million square feet, currently in production at the end of the third quarter.
  • Preferred Equity Dividend Lever -- $12 million, representing potential annual cash savings if the company chooses to convert cash dividends to payment-in-kind.

Need a quote from a Motley Fool analyst? Email pr@fool.com

RISKS

  • Kazan stated, "The trim mix issue persisted into the third quarter, and our CFO estimates it cost us in excess of $10 million," noting the significant impact of the unfavorable sales mix on financial results.
  • Kazan warned that "California wholesale price remains compressed relative to other markets and prior years," a factor the company does not control.
  • Vendetti noted that fourth quarter pricing "typically softens versus Q3" due to historical seasonal variations in the California market.
  • Farrar warned that "the cogen being down has multiple impacts, one of which is that we don't have all the power we want to turn all the lights that we want," which negatively affected production yields and light assistance.

SUMMARY

Glass House Brands (NYSE:GLAS) reported third quarter revenue of $56.8 million and record biomass production of 319,000 pounds while navigating an unfavorable product mix and wholesale price compression. Management reported that the company completed the deconsolidation of its retail operations and successfully uplisted to the New York Stock Exchange during the period. Operational focus remains on optimizing Greenhouse 2 and Greenhouse 5 to improve the ratio of high-value flower and smalls in the production mix. The company reported a cash balance of $39.7 million, which management stated is sufficient to fund its $20 million capital expenditure plan and reach positive cash flow. Strategic initiatives include preparing for potential interstate and international commerce following the transition of medical cannabis to Schedule III and obtaining international quality certifications for existing farms.

  • The company received Good Agriculture and Collection Practice certifications for its Casitas and Padaro farms, which management indicated are critical for entering international medical markets like Germany and Switzerland.
  • Management reported the full activation of Greenhouse 2, which includes 11,000 lights designed to mitigate seasonal production fluctuations and improve cannabis quality.
  • The company paused its hemp operations after determining the financial results did not justify continued investment under current market and regulatory conditions.
  • Chief Financial Officer Mark Vendetti announced his retirement effective at the end of March 2027, with the company initiating a search for his successor.
  • The company reappointed MGO as its auditor after a brief tenure with BDO, citing BDO's inability to complete the third quarter review by the regulatory deadline.
  • Kazan indicated that he does not intend to ask for an extension of the multiple voting shares, which are currently scheduled to expire at the end of June 2027.
  • Farrar noted that while production mix improved during the third quarter, the lag between harvest and sale means the financial benefit of these improvements will be more visible in future periods.

INDUSTRY GLOSSARY

  • 280E: A section of the U.S. Internal Revenue Code that prevents cannabis businesses from deducting ordinary business expenses from their gross income.
  • ASP: Average Selling Price, the mean price at which a company sells its products over a specific period.
  • Biomass: The total weight of the cannabis plant material produced, typically including flower, smalls, and trim.
  • CPG: Consumer Packaged Goods, referring to products sold to consumers in finished, branded packaging.
  • GACP: Good Agriculture and Collection Practice, a set of international standards for the cultivation and primary processing of medicinal plants.
  • PIK: Payment-In-Kind, a type of dividend or interest payment made in additional securities rather than cash.
  • Smalls: Lower-grade cannabis buds that are smaller in size than premium flower but higher quality than trim.
  • Trim: The leaves and stems removed from cannabis buds during the harvesting and curing process, typically used for extracts or lower-priced products.

Full Conference Call Transcript

Operator: Good afternoon, ladies and gentlemen. Welcome to the Glass House Brands Third Quarter 2026 Earnings Call. Matters discussed during today's conference call may constitute forward-looking statements that are subject to risks and uncertainties relating to Glass House Brands' future financial or business performance. Actual results could differ materially from those anticipated in those forward-looking statements. The risk factors that may affect results are detailed in Glass House Brands' periodic filings and registration statement. I'd also like to remind everyone that this call is being recorded today, Monday, November 16, 2026. On today's call, we have Kyle Kazan, Co-Founder, Chairman and Chief Executive Officer; and Mark Vendetti, Chief Financial Officer. Also joining for questions is Graham Farrar, Co-Founder and President.

And with that, I'll turn the call over to Kyle Kazan. Please go ahead.

Kyle Kazan: Thank you, operator. First, I'll be discussing Glass House Brands' recent financial performance, along with the company activities. Then our CFO, Mark Vendetti, will share the financials, after which I will wrap up before the 3 of us take your questions. As the Co-Founder, Chairman and Chief Executive Officer since day 1, I'm one of the key architects of how our company was built and who we are today. Since that day, Glass House Brands was built to be a company for the future for the day when California cannabis would be legally accessible to consumers around the country and the world.

However, we have been prepared and still are to succeed completely within the confines of our state until the walls come down and we are allowed to ship across our borders. We are well positioned as the Golden State has the beautiful California sunshine, appellation due to generations of legacy growers who created amazing strains and the most discerning consumers of this wonderful plant. At Glass House, we are the largest cultivator on the planet, owning 6 million square feet of greenhouses. We have not turned on our entire footprint and still have room to expand when we can sell outside of California.

Even though harnessing mother nature is not always easy, I proudly stand by the decision today to be a greenhouse grower in California as most cannabis grown around the country is being done in warehouses at multiples more expensive than our costs. But the road not travel is certainly not easy as evidenced by our recent financial performance. As most of you know, pricing in California has been challenging when compared to other markets. As such, the average price outside of California is far higher than it is within our state. When interstate commerce becomes the reality, California pricing will improve and consumers in higher-priced states will get relief.

The net effect, we believe, will be substantially higher pricing than what we are currently seeing in California. To that end, since medicinal cannabis became Schedule III, a company priority has been to work closely at the highest levels with the California Department of Cannabis Control, or the DCC. Our consultant, Matt Murphy of Pharma Compliance Group, is working with both the DCC and the Drug Enforcement Administration to understand how we can access other markets as soon as possible. Although interstate commerce is not currently a reality, we will remain focused given its importance to Glass House and consumers everywhere.

As we look outside of California, in October, we received Good Agriculture and Collection Practice, GACP certifications for our Casitas and Padaro farms from Perry Johnson Registrars Food Safety. These certifications confirm that the facilities meet the strict international and interstate safety and quality standards required for medical cannabis markets, and they represent a critical step towards supplying those markets both domestically and internationally once export is permitted. Together, the 2 farms comprise more than 0.5 million square feet of advanced greenhouse cultivation, making them amongst the largest GACP-certified facilities in the United States. Markets such as Germany, the U.K. and Switzerland require GACP-compliant operations.

So these certifications expand our pathway to higher-priced medicinal markets and a meaningful larger addressable opportunity as regulatory environment continues to evolve. Now turning to our third quarter results. Third quarter revenue was $56.8 million. We produced 319,000 pounds of biomass during the quarter, a record for the company and ahead of the 246,000 pounds produced last quarter. Third quarter cost of production was $109 a pound compared to the $122 per pound reported in the second quarter of 2026 and $175 per pound in the first quarter. This marks more than a 37% cost production improvement since the first quarter.

The improvement comes from continued operational efficiency enhancement as our workforce gains experience every day, and we benefit from higher production volume across a larger footprint. We remain on track to produce approximately 1 million pounds of biomass this year and exit the year with cost of production around our current level with our long-term target of $95 per pound intact. In the second quarter of 2026, it became clear that we were growing less flower and smalls and more trim. The trim mix issue persisted into the third quarter, and our CFO estimates it cost us in excess of $10 million.

As such, our average selling price for the quarter was $151 per pound, down from $211 per pound last quarter. Let me address this decrease directly. The ASP is the combination of 3 main factors: the trim mix we sold, the yields we achieved on flower and smalls and the underlying market. The largest driver this quarter was mix. We sold a higher proportion of trim, roughly 63% of pounds sold versus the high 40s and low 50s we saw in prior periods and well above our historical best of around 45%. Flower and smalls together made up only about 37% of sales.

In 2024, for comparison, flower alone was closer to 37% in that quarter, and our 2027 projections target a meaningfully better mix. Part of this is timing. As we finished the second quarter with higher inventory levels than expected, we sold more inventory in the third quarter from earlier production periods that were more trim-heavy. The production mix improved during the quarter, and we expect further improvement in the fourth quarter. Because of the normal lag between harvest and sale, the sales mix in any given quarter does not fully reflect the production improvements already underway. Production quality and mix better indicate where we are heading.

Had we sold the mix that we actually produced during the quarter, the ASP would have been higher at today's prices at $180 a pound, about $29 higher per pound than we had achieved. As previously stated, the market is a factor as well. Flower pricing in the second quarter of '26 was actually slightly higher than the prior year. However, in the third quarter, that reversed and flower sold in the high 300s a pound this quarter versus the low 400s a year ago. California wholesale price remains compressed relative to other markets and prior years, and we do not control that.

Pricing is also subject to normal seasonal variation and has been softer in the back half of the year, consistent with historical patterns. What we do control is the mix and the yields, and those are the areas where we are focused. On the production side, flower and smalls per square foot ran below 2024 levels this summer. The drivers are similar to what we talked about last quarter. The genetics we had to plant coming out of last year's disruption, a large share of the workforce still early on the learning curve as we expanded capacity and the temporary off-line status of a cogeneration unit that limited CO2. Wetter weather in the first half also played a role.

These are near-term issues, not structural ones. The important point is that we are already seeing the [ turn ]. Production mix improved during the third quarter relative to the prior quarter. Operational changes, better screening, healthier plants, improved defoliation and day-to-day execution are showing up in the numbers. We are seeing an improvement in production mix and continued progress on cost of production. These operational gains are not yet fully reflected in the financial results given the timing of sales, but they give us confidence that the trajectory is improving. It's also important to note that none of the larger capital investments we already have underway or have planned are yet reflected in these results.

These investments are designed to further improve yields, mix and consistency as we move through 2027 to optimize Greenhouse 5 and 6. The capital we are deploying is directed toward facility upgrades and process improvements that are intended to improve yields, mix and to support further reductions in cost of production. We recognize that the third quarter fell short on mix and average selling price. Since last year's disruption, greater scale and the use of third-party processing have made the lag between harvest and sale less predictable than it was previously, and we are working to improve that visibility. Looking to the fourth quarter, we expect the sold mix to continue improving.

Our current forecast has flower and smalls together approaching 45% of pounds sold, up from 37% in the third quarter, even as flower pricing follows its normal seasonal decline from the high 300s into the low 300s. The blended ASP may, therefore, remain soft in the fourth quarter, but the underlying production quality and mix appear to be heading in the right direction. As pricing typically strengthen seasonally in the first quarter, we should see the benefit of the improved mix more clearly. During the third quarter, we also made the decision to pause our hemp operations after determining that the results did not support continued investment at this time.

This action allows us to concentrate resources on our core cannabis cultivation business where we continue to see stronger opportunities for returns. We will remain disciplined in evaluating any future hemp-related opportunities should market conditions or the economics improve. When we're getting back on our feet during the quarter, we also turned on Greenhouse 2 which boasts 11,000 lights powered by our cogeneration facilities. Frankly, it is this greenhouse we are most excited about when we first visited the facility in October of 2018. Those lights changed seasonality compared to non-light-assisted greenhouses, and we believe they would produce some of the best quality cannabis on the planet.

In retrospect, while our excitement about Greenhouse 2 remains, turning on another massive greenhouse while we were continuing to train and expand a new workforce took up a lot of the team's bandwidth and the focus. Given the prerelease of our third quarter earnings, where we announced that we had $39 million in cash in the balance sheet, which we believe is enough to get us to cash flow positive, I want to address some of the tools that we have to get us there. An amazingly gritty team, I have never been luckier to call a group of individuals, my long-time teammates than I am now, and I'm always amazed at how we execute even during challenging times.

Our preferred equity, as we created both existing rounds internally, we were deliberate that if necessary, we could forgo cash dividends and convert them to payment-in-kind. While we have never done this, it is a lever we can pull, which would save us almost $12 million over the course of the year. Our $50 million in corporate debt, we chose a sophisticated bank, which has been very supportive. They have recently granted us a waiver for an additional 4 quarters of loan covenants, given us further financial flexibility as we continue to address near-term concerns and prepare for a world with interstate commerce.

Our deeply experienced team knows the California cannabis market inside and out, and we will make whatever changes are necessary within our organization so we have absolutely what we need to succeed. At the end of June 2027, the multiple voting shares will expire, and I do not intend to ask the Board of Directors and shareholders to extend them. I also want to briefly address my related party transactions disclosed in our filings as we know this is an area of interest for investors. As you will hear, many have already been terminated or in the process to terminate. Some of these relate to real estate leases for retail properties.

Several of these properties are partially owned by me, including through Beach Front properties and related trusts. It should be noted that the retail properties have been deconsolidated from Glass House Brands and the lease obligations are with Glass House Retail. A couple of items worth highlighting. One of the retail leases with 2000 De La Vina LLC was terminated in 2025 in connection with the sale of the underlying property. Subsequent to September 30, 2026, an agreement was entered into with 2000 De La Vina LLC, under which the remaining termination payment obligations under the terminated lease would cease effective October 1, 2026.

In August 2025, Glass House Brands acquired the remaining 76% undivided ownership interest in the Lompoc property that had been leased from Neo Street Partners. This acquisition eliminates future related party ownership and rent expense associated with that facility. In the case of the lease of our corporate headquarters, which is owned by an entity in which I have a 50% ownership stake, the lease was renewed effective January 1, 2025. In 2026, the lease was modified in favor of Glass House Brands, allowing the company to terminate at its options with 30-day notice. Glass House Brands is evaluating its office needs and is strongly considering terminating in 2027 as part of our company optimization planning.

Outside of the leases, we had a long-standing consulting agreement with Beach Front Property Management for M&A advisory, real estate acquisition and financing service. The agreement allowed Glass House Brands to raise significant capital without using investment banks and broker-dealers, saving many millions of dollars in fees for the company. I controlled Beach Front Property Management through the Kazan Trust, which owns 51% of its parent holding company. The agreement was terminated on September 18, 2026. This termination eliminates the related party contract going forward. We have used Jon A. Neu Insurance, which is a majority owned by Beach Front Properties as a vendor for insurance brokerage services.

When we first started the business and made these arrangements, it's important to remember that the cannabis industry was much different than it is now. Regulatory reform was nowhere near where it is today and getting insurance in cannabis was difficult. In 2026, Glass House Brands instituted a formal process to obtain request for proposals for all company services. We expect to choose a nonrelated vendor by the end of this year. My family trust, related entities and my children's trusts are invested in the Series D preferred issuance and the E convertible preferred issuance and participate in the conversion of certain earlier series into Series E.

All of these transactions were completed on the same terms and conditions as those applicable to nonrelated party holders. No preferential rights or special arrangements were provided. Full details of each arrangements, including related party rent and other expense amounts are included in the related party transactions note to our consolidated financial statements available on SEDAR. I'm happy to take questions on any of these items. Now before I turn the call over for our financial review, I'd like to recognize Mark Vendetti, who recently announced he will be retiring from his role as Chief Financial Officer at the end of March 2027. Mark is only the second CFO in Glass House's history.

And over the past 5 years, he has been a dedicated member of our executive team and a true friend to many of us, including me. He has guided the company through significant milestones, including this year's deconsolidation and New York Stock Exchange uplisting and his contributions have been important to where we stand today. We are grateful for his commitment and the work he has done. We have initiated a search for his successor. I'd also like to note that as previously announced, John Nichols, Jr. has resigned from our Board of Directors. We thank Jay for his service to Glass House and wish him well in his future endeavors.

I am hyper-focused on filling these key roles, including adding independent directors for both audit and medical roles. Interviews are underway, and we will introduce new leaders as appropriate. With that, I will turn the call over to Mark Vendetti, our Chief Financial Officer, to discuss our financial results for the quarter in detail. Mark?

Mark Vendetti: Thank you, Kyle. Good afternoon, everyone. Before I get into the numbers, I want to note that all prior period results discussed today reflect continuing operations. As a reminder, we recast our historical results to exclude Glass House Retail following its deconsolidation on June 12, consistent with how we presented our second quarter financials. So the comparisons I'll walk through, including our third quarter 2025 figures are on the same consistent basis. Third quarter revenue was $56.8 million, up from $26.2 million in the third quarter of 2025. This is comprised of $50 million in wholesale biomass and $6.3 million in CPG sales, which compares to $21.2 million and $5 million, respectively, in the third quarter of last year.

We produced 319,000 pounds of wholesale biomass in the third quarter, up from 246,000 pounds in the second quarter and 124,000 pounds in the third quarter of 2025. Third quarter cost of production was $109 per pound compared to $122 per pound last quarter and $128 per pound in the third quarter of 2025. The improvements reflect continued operational efficiency gains as our workforce matures and we benefit from higher production volume across a larger footprint. At the end of Q3, we had over 2 million square feet of licensed cultivation in production. We sold 329,000 pounds of wholesale biomass in the quarter, up from [ 137,000 ] pounds last year in the third quarter.

Third quarter gross profit was $14.6 million and gross margin was 26%. Gross margin compares to 34% last quarter and 21% in the third quarter of last year. As noted in our preliminary results announcement and as Kyle mentioned earlier, while seasonally lower pricing and trim heavy sales mix from Q2 production pressured margin during the third quarter, higher volume kept gross profit close to what we reported for the second quarter. Adjusted EBITDA for the third quarter was positive $0.8 million compared to positive $5.7 million last quarter and negative $2.3 million in the third quarter of 2025.

The decrease in Q3 adjusted EBITDA versus Q2 is primarily driven by higher professional fees related to uplisting to the New York Stock Exchange and consulting fees related to SOX as well as lower gross profit. Third quarter operating cash flow was negative $0.1 million compared to positive $0.2 million last quarter and negative $5.1 million in the third quarter of 2025. It's worth noting that last quarter's and prior year quarter's figures include the operating cash flows of our former retail business, so this isn't a fully like-for-like comparison. We ended the quarter with $39.7 million in cash and restricted cash compared to $22.1 million last quarter.

During the quarter, we raised $10.1 million in proceeds from the accelerated call of the company's Series B, C and D preferred equity warrants. In total, we issued 4,848,000 shares from the redemption of these warrants. We also raised $18 million in net proceeds from the company's at-the-market facility, issuing 2,262,000 equity shares at an average price of $8.11 per share. In total, we raised $28.1 million in proceeds and issued 7.1 million shares. At quarter end, the company had no outstanding warrants left. These actions demonstrate our efforts to meaningfully simplify our cap table.

After the quarter end, in October, we raised an additional $3.6 million in net proceeds from the at-the-market facility, issuing 708,000 equity shares at an average gross price of $5.16 per share. We currently have no plans to use the ATM beyond what was raised in October. We believe our cash position at the end of September is sufficient to allow the company to execute its business plan, including $20 million of CapEx investment designed to improve production, primarily of high-value flower and smalls and move through the seasonally lowest period of cash lasting through the first half of 2027. Turning to guidance. Our target of roughly 1 million pounds of biomass production for the year remains unchanged.

We expect fourth quarter cost of production to be in line with the $109 per pound reported in the third quarter. Continued operational improvements helped offset lower seasonal production in Q4 versus Q3. This will get us back to our Q4 record low production achieved in 2024 of $110. Our long-term target of $95 per pound remains intact. I want to conclude my remarks by addressing our recent change of auditor as there's been some confusion about it. In September, MGO resigned as our auditor upon request. This was to appoint BDO who we chose as our new auditor based on their experience and stated ability to meet our Q3 reporting deadline of November 16.

However, in mid-October, BDO advised us that they had not completed their review of the accounting of the deconsolidation transaction we completed earlier this year to facilitate our listing on the New York Stock Exchange and suggested the possibility of filing Q3 results without completing their review. This was disconcerning as the ability to complete review of 2026 transactions and filing Q3 results on time was discussed with them prior to our engagement. We found the prospect of missing a reporting deadline or not filing with an auditor's review is suggested to be unacceptable for our shareholders.

Therefore, we reached out to MGO, who previously reviewed the company's accounting for the deconsolidation and completed this review without identifying any material modification. MGO indicated that it expected to complete the Q3 review within the applicable filing time line. This is why we decided to reappoint MGO as the company's auditor. BDO concluded this was an unresolved issue because they did not finish their review when we told BDO we were going back to [ MGO ]. We believe their interpretation of the applicable Canadian reporting rule is wrong as no resolved issue would arise unless they completed their work and we did not agree. We were obliged to disclose BDO's position even though we believe BDO is wrong.

As a result, we issued a press release to meet regulatory requirements. As you can see, we have met our reporting with MGO deadline as we are here today. Also, I want to point out that BDO did not actually issue an auditor's report or a review report on our financial statements during its brief tenure with us. And with that, I'll turn the call back to Kyle for closing remarks before opening up the call to Q&A.

Kyle Kazan: Earlier this year, President Trump gave a full pardon to Jerry Haymon, a former cannabis prisoner from Fresno, California. Thanks to that decision, we were finally able to hire him, and I'm proud to be Jerry's teammate. There are many more like him still serving a hard time, some with life sentences, and we hope that our President will continue to change the lives of more prisoners of the war on cannabis. Heading into 2027, we are encouraged by the progress we are seeing on the farm. Production mix improved during the quarter. Cost of production continued to come down, and we remain on track for approximately 1 million pounds of biomass this year.

The capital we are deploying is directed towards tangible facility upgrades intended to improve yields and mix and to support further cost reductions. There is still work to do to get yields and mix back to the levels we expect, and we are focused on finishing that work. At the same time, the GACP certifications received in October, together with the medical Schedule III framework, give us the building blocks toward higher-priced domestic medical and international markets. In those markets, the same production and an improved mix supports a much greater economic result for Glass House.

The operational issues still need to be fixed, but the structure we have built is intended for that broader opportunity that has only gotten better over the past 12 months. I want to thank the entire Glass House team for the work they have put in this year between optimizing the farms, completing the deconsolidation uplisting and preparing for the opportunities ahead, the team has shown continued dedication, and I'm proud to lead this group. Please consider coming to our investor session in June, so you can meet our amazing team and tour the finest cultivation facility in the entire world. Thank you again to everyone who joined us today.

I will now ask the operator to open the line for questions.

Operator: [Operator Instructions] Our first question comes from the line of Frederico Gomes with ATB Cormark.

Frederico Yokota Gomes: First question about the mix of trim and flower. I appreciate the color you provided there. When do you expect to actually reach, I guess, the target mix that you think you can get out of your facilities? And I believe in Q2, you mentioned there was an issue with a cogeneration unit that was offline. Did that still have an impact in the mix for Q3 and Q4 as well? And is there any meaningful costs associated with that, I guess, with fixing that cogen plant?

Graham Farrar: I can take both of those. Thanks a lot for the call, Federico. So a couple of things. One is on the mix, just as a reminder, that Q3 was record production for biomass and flower. So we grew almost 317,000 pounds of biomass, which was about a 30% increase and a record for the company at any time, both of total biomass as well as flower. So I want to make sure that it doesn't get lost in there that the work we are doing is actually record setting. What we're talking about when we talk about the mix is there's 2 ways that you can have a higher mix of trim. One is to have more trim.

The other is to have less flower. More trim is not a problem. It's the less flower that is. In the front half of the year, particularly in Q2, our flower yield on a square foot basis ran about 25% lower than [ it did in ] our best-ever quarters. So as we move through that, once we've grown it, now the sales has to sell it. So a lot of what we saw in Q3 was actually selling through the trim heavy inventory that we produced in Q2. The good news is that operationally, the production leads sales.

So while we were about 25% below historical best ever in Q2, in Q3, what we actually produced, we closed the gap to about 10%. And so far into Q4, we're running currently in the single digits. So the team is rapidly making progress getting back to our best-ever historical baselines, and we can already see it happening in the production that's actually being put into inventory, which, of course, harvest lead to production, production leads to sales. So in the pipeline, if we look at one step before where the sales are, that production is rapidly improving and not -- at this point, not very far away from our historical best ever.

Now I will say to be cautious because in Q4, we tend to see a seasonally lower prices. So a lot of that operational improvement may get swallowed up in the lower prices that are typical for that time of the year, but the operational improvements will be durable. So when we head into the front half of next year, we should see the benefits of that when the prices start to come back up. There's two primary components behind those challenges. One is operational, which we can see that we're already fixing. The other is facilities, which is where we've launched some projects to make some improvements.

We had a tough time this summer, particularly in Greenhouses 5 and 6 with their ability to cool the greenhouses, fans that weren't moving as much air as they used to, resulting in the growers trying to screen to control temperature, which hurt light and impacted yields. So we've been able to make a bunch of improvements operationally there. The next step is actually going to be to upgrade the facilities, which should get us not only back to our historical baseline, but should give us the opportunity, particularly with Greenhouse 2 to do even better than that. On your cogen question, yes, the cogen has been offline for a bit. There's 3 things that we get from the cogen.

One is electricity, which we used to sell and still do in the heating time, but predominantly used to run the lights in Greenhouse 2. The other thing you get from it is heat and CO2. Every one of those is valuable at a farm, which is why the cogens are so nice to have. We can make electricity at $0.08 a kilowatt instead of buying it for $0.28 and we get that free heat and the free CO2 at the same time. Now that we have the light, the cogen being down has multiple impacts, one of which is that we don't have all the power we want to turn all the lights that we want.

And the more light we have, the better yields we have. The other, and this is something we've historically had that we've been without is the exhaust from that cogen that we put into the greenhouses and the CO2 helps improve yields. It also makes the plants more tolerant to heat. So with not being able to supplement with that CO2, it reduced the yields. The plants don't grow as fast and they grow bigger leaves rather than the bigger buds that we're after. So they just did the commissioning on that. The engine has been worn in. And if things go well sometime this week, we'll actually see it go back into service.

So we have not had any of the benefit of it up until at this moment. But hopefully, before this week is over, we will see that change. Plant growth cycle is about 60 days from there, another 30 days to process it and then a little bit of time to sell it. But as soon as we can start putting that CO2 back into the greenhouses, we will get the benefit from it and the crops that are in there will start to reflect that when they're harvested.

Frederico Yokota Gomes: Great. Appreciate that. Second question, I believe that I guess interstate commerce and exports are a big part of the story here. Can you talk about the realistic, I guess, time line for that to actually happen? When do you expect to actually be able to, I guess, have a first export shipment out of California? And in terms of supply agreements, I believe in the last call, you mentioned you would expect, I guess, a supply agreement by the end of the year. I guess we're approaching that. Is that still -- do you still stand by that potential supply agreement this year?

Graham Farrar: Maybe I'll take the first half and Kyle can talk to the supply agreements. So on the DEA part, I'm going to back up a little bit there. The timing of when they do it certainly is not something that's in our control. I think there's been quite -- there's been a lot of confusion, which I totally understand on this topic. I do think people are missing the forest for the trees a little bit. The forest is that this process is actually happening. I mean we can, at this point, say it has happened. There are now 900-plus stores federally allowed and licensed by the DEA to sell cannabis, right?

Like that is a step change, a paradigm shift, 50 years of cannabis prohibition that has now at least started to end, right? Like there are stores today, as we sit here, can sell cannabis federally legally. There's a lot of questions about how does that happen in the letters that are going out. I think it's worth noting that no licenses have been rejected yet. There have been letter -- not to say they won't be, but they have not been yet. There are letters to show cause, they call them, which have been issued to some dispensaries, which also hold adult-use licenses.

No letters have -- no show cause letters have been issued to any operator who holds only a medical license, which is what Glass House does. So right now, it's an open question, right? And so if you think about what it means, they're basically telling these stores that also sell adult use why they shouldn't be denied, right, which is, I think, understandable from the DEA's point of view. The ALJ hearing hasn't concluded. So if they're applying their playbook and they don't have adult use in it, kind of what else can they say at this moment. I think the key piece there, though, is they're applying their existing playbook, right?

They are treating cannabis as a Schedule III drug. There is no Schedule III drug that's not available in all states. There's no Schedule III drug that doesn't ship with interstate commerce. There's no Schedule III drug that doesn't have international exports. So the fact that they're applying the Schedule III rule book all the way down to the ledgers that they use to transfer the product is the key piece. The process is happening, the football is in the air. And of course, there are things that have to be worked out, right? There's no question. There's never been the opportunity to interface state and federal programs together until now. So will they get figured out?

Yes, because now they can be. So I think it is certainly something that we're watching closely. Don't know the exact timing. But to me, it's very encouraging that there actually is a process to work on because we've been waiting 50 years for that. If the DEA maintains a stance that says any licensing program with adult use isn't eligible, the result of that would be 55% of the population is not covered. 85% of the cannabis sales are not addressed. You've built a system that isn't really a system if you leave 85% of it out. So I don't think it's either tenable from their side.

If they stick to that, though, you can -- I can guarantee the states are going to adapt to it, right? If California needs to make a licensing regime in California and 24 other adult-use states plus D.C. need to make licensing regimes that fit the medical model like we had for the first 25 years of legal cannabis in California under Prop 215, then they will because otherwise, their operators are going to be left out with no 280E, et cetera, et cetera. So one way or the other, these pieces are going to get put together. I think the exciting part is that we finally have the opportunity to work on that.

I mean you've got cannabis being sold in Georgia in pharmacies. I'd encourage people to look up where Trulieve just started. We're talking regular shops, right? Boots in the U.K. just started selling their equivalent of the CVS is now selling a -- have a medical cannabis program, right? So like all this normalization is happening, and I think that's the important part to focus on. We're doing everything on the GACP, did it for Padaro, did it for Casitas. Now we're working on Camarillo. The team there is even working on what we can do on the GMP side.

So we're putting in all the foundational pieces for when this goes together because those are the standards that we expect to be required and the fact that there's a system that we can now work with is the opportunity that we've been waiting a long, long time for.

Kyle Kazan: And I'll follow up -- Thank you, Graham. I'll follow up, Frederico, in regards to interest for our supply. There is absolute interest in other states for our cannabis and also internationally. There's really nothing to press release because while they said, Hey, we really want your cannabis and we say, we really want to get it to you. Right now, we don't have enough information that if we put out a press release, I think people would be saying, when is this going to happen? And we just need a little bit more guidance. As Graham was describing, we think it's coming.

But until it does, we just -- it would be more fluff than anything else at this point. But suffice to say that buying something from us growing at $109 a pound from California versus something that's grown at $800 a pound in a warehouse in Canada, it's an absolute no-brainer for folks internationally and also in other states. So I wish I could just say, hey, here are all the details, but lacking some of those very important details, we're just not going to go ahead and PR.

Operator: Our next question comes from the line of Kenric Tyghe with Canaccord Genuity.

Kenric Tyghe: I appreciate all the incremental color on tonight's call. Can we just push a little harder here on -- so improving mix, trim 63% to 55% in the fourth quarter, operational improvements supporting improving yields and obviously some pricing headwind that you called out. I think what perhaps we need to try and triangulate and hoping the team can do it is a better indication of some sort of bridge on how does that translate in terms of average selling price range here in the fourth quarter? And any commentary around the gross margin range given the fear that is currently baked into the share price.

I think any incremental color there would obviously be particularly useful if you could translate the moving parts here into some ranges that we could start to work with or work around.

Graham Farrar: I can take the operational part and maybe, Mark, you want to do margin?

Mark Vendetti: Yes. Yes. Go ahead, Graham, and then I'll talk about -- I'll talk numbers.

Graham Farrar: Great. Yes. So it's totally fair to push. Obviously, it's a big deal. The best -- the way that I prefer to think of it is less about the percentages and more about the yield, which, as I mentioned, we started the front half of the year about 25% lower than we would historically have been. And we've closed that gap in Q3. It was about 10 points lower than historical. And so far into Q4, it's only about 5 points behind. Of course, we don't just want to get back to where we were, we want to get better. So plenty of work to do.

And again, with Greenhouse 2 in the mix now, we should be able to do not only as good but better than we have been. So there's -- I think that probably the best way to think of it is if we had sold what we actually produced in Q3 rather than having to work our way through the trim-heavy inventory that was produced in Q3, Q2, I'm sorry, at Q3's prices, the ASP probably would have been more in the $180s instead of the $150. So there's quite a bit of upside there. Team did a phenomenal job dropping another 10% or so in price.

That makes us about a 40% price reduction from the beginning of the year from $179 to $109. It's also for reference, I think it's about $5 or $6 away from our best ever Q3 historically. So the pricing is also getting back into the range that we would expect it to be, which I think is best-in-class. We're currently in second place, but second place to what we've achieved ourselves historically. And based on what we're seeing for Q4, I would say we probably get back and match our best ever Q4 COGS as well, which are 2 ways to help margin, right?

One is higher pricing, better -- and the other is lower cost and then more pounds to maximize gross profit. So I think we're making good progress on both of those. That said, as I mentioned, Q4 pricing typically softens versus Q3. So even with an improved mix, some of those gains are likely to be hidden until we get the pricing swinging back the other way in the front half of '27. Go ahead, Mark.

Mark Vendetti: Thanks, Kenric. So just a couple of numbers that you guys can deduce from what we've said. Given our year-to-date production and to get to 1 million pounds for the year, I think that means we have to do 284,000, 285,000 pounds of production in the fourth quarter. We -- I'm going to say we generally -- now that inventory, I think, is better aligned and we work through some of the higher inventory levels in Q3, I mean, we're typically going to sell 10,000 to 15,000 pounds less because that's how much we end up sending over to our CPG unit.

The other bit of information we provided is we said pricing is going to fall on flower from kind of the high $300s to the low $300s. So you're going to have -- if you go -- I'm going to mix up out of trim, which trim, let's call it, $15 to $20 a pound into flower, which is, let's say, selling at a low $300, that's going to help the ASP quite a bit. But on the flip side, you're going from a high $300 to a low $300.

So when you put both of those together, as I think we've said, there probably is not going to be a significant change in the average ASP for Q4 versus Q3. And again, this is an easy general rule of thumb to help with margin. And there may be a few percentage point difference quarter-to-quarter. But if you look at the average selling price you calculate or forecast minus the cost of production in that quarter and just go -- and it was very close for Q3 as an example, if you take $151 in Q3 minus $109 cost of production, it gets you to a 28% margin, which was actually pretty damn close to what we reported.

So I would work through an ASP number. We kind of already gave you our cost of production number for Q4, and that will help you figure out what gross margin should be in Q4.

Kenric Tyghe: I appreciate the color. I was wanting to just try and tie a little more closely because I think obviously, a lot of noise and expectations and a lot of fear and expectations. What I'm hearing from you, Mark, is that this is a high 20s on rough math. We probably don't push back into that low to mid-30s until the first quarter of 2027. Is that a fair characterization?

Mark Vendetti: So I would actually -- I think if you look at gross margin, it should be very similar to what Q3 is because the underlying ASP is not going to be much different and the cost of production is not going to be much different. The dynamics are going to be different. Again, more flower, but offset by lower price is going to get you back to roughly the same consolidated average selling price.

Kenric Tyghe: Appreciate that. And then just with respect to a quick follow-up on the -- while it's a small part of the story, it was certainly gathering some headlines earlier in the year. Your hemp pause, as you put it, is that just a reflection of sort of the kind of a state level driven reset given some of the regulatory headwinds and changes? Or is that something that was within your control and you're sort of stepping back for reasons other.

Graham Farrar: I can take that one. I mean a lot of it is just want to give some clarity on what the regulations are. We -- the things are moving pretty dynamically right now. Technically, the ban -- the first phase of the ban took effect a few days ago. The next phase is unless something changes currently slated to take effect, if they put in the McConnell language, there's just not a whole lot that fits within that definition, 0.4 milligrams of THC per package, like I mean, even balms and things like that don't fit within that. So while we're certainly hoping that there's something that more common sense that comes along.

Right now, it's a pretty tight window, and it looks like we'll at least have clarity one way or the other in the next, call it, 30 days or so. So wanting to make sure that we know what we're operating to. Also, as we discussed, right, like plenty of work to do on the core business. So while we have one thing that we know we're good at, and we know how to make that work, and we want to get that back to best ever performance and the other, which is moving around pretty quickly, I thought it made sense to focus in on the one, get clarity on the other and then reevaluate.

Mark Vendetti: Kenric, one other point, though. We were -- I mean, we were disappointed with the overall financial results we were getting. And you combine that with what Graham said, it just made sense to kind of step back and pause and see what's going on with the broader environment.

Operator: That concludes the question-and-answer session. I would now like to turn the call back over to Kyle Kazan for closing remarks.

Kyle Kazan: Thank you, operator. Graham, did you want to make a statement or a comment?

Graham Farrar: Yes. I just wanted to say I don't think we've ever had more people on the call. So I'm sure that a lot of people are here wondering what's going on. Obviously, the decline in the stock is not lost on anybody, though not directly addressed here. And I just -- I wanted to say that we got plenty of work left to do, but I think our demise has been greatly exaggerated and step back for a second and kind of remember the why and listen for the signal through the noise, so to speak.

What we do here at Glass House is hard and not to be overly philosophical, but we [ photons ] from outer space and turn it into a product that at least we think improves the human condition. Walking on the farm looks nothing like our stock price. I think the farm is looking as good as it has looked. It's looking the best it's looked since the [indiscernible]. And I just want to say that -- I want to say I'm incredibly proud of the team at the farm. I think every day, I see them put passion, love, caring, hard work into what they do. At this point, they've done what a lot of people said was impossible.

They rebuilt the largest cannabis greenhouse on the planet from scratch with a workforce that's been vetted like no other in agriculture. And the farm just it looks beautiful. It's a really interesting juxtaposition to walk through there with a smile on my face again for the first time in a while and then walk out and see the share price next to it because the things are very disconnected. So there's clearly a lot more to do, but the progress the team is making and continues to make is remarkable. I think Glass House continues to be incredibly well positioned for the goal that we set out for ourselves.

The reality is you can't solve 3 million square foot problems at 30,000 or even 300,000 square feet. And because of the work the team has done, we're lucky to have the opportunity to work on those. They're not easy, but they are the problems that need to be solved for the world that we believe that we're building for where cannabis is normalized and it's on every shelf and you need a supply chain that can support national and global markets. And I don't think there's another team out there, partially because of all the hard work that they've done, that even has a chance to solve those problems. It humbles me to work alongside them.

I believe what we do matters. I think more and more society is realizing that as well and that cannabis is part of the solution that we're identical with nature and that nature has the answers to a lot of our problems and cannabis is part of that. The federal government now agrees, which is awesome that cannabis is medicine that joins Canada, Germany, the U.K. and growing list on a daily or monthly basis. As I mentioned, cannabis is now being sold in pharmacies in Georgia as well as Germany. The U.K. just launched a medical cannabis program.

So just a reminder to keep your ear out for the signal through all the noise because whatever the weather looks like in the morning, the thesis hasn't changed. The operations are getting back to their best. The destination is the same. We're closer to it than we've ever been, which is kind of ironic with everything else going on. And if you ever believe that we were the right team in the right place at the right farm, doing the right thing, that is as true now as it has ever been. We certainly didn't come this far to only come this far, and we're going to get where we're going.

That's the important part, I think, and I appreciate everybody showing up to listen.

Kyle Kazan: Thanks, Graham. And if I can just finish up by saying I've been asked by a lot of people about our share price, and am I regretful that owning millions of shares, I didn't sell near the peak. And I said, absolutely not. I'm a long-term investor since day 1. I don't like that our stock has been on a wild ride for sure. But at the end of the day, I believe to my soul, that the best days of our stock price are ahead of us and not in the rearview mirror. So I'm still a very happy shareholder, and we'll be happier when we hit new record prices in the future.

And as Graham said, we are built for the future, and we look forward to it. All of that said, thank you, everybody, for joining our call, and we look forward to seeing you at the farm and on future investor calls. Thank you, operator.

Operator: Ladies and gentlemen, that concludes today's call. Thank you all for joining. You may now disconnect.

This article is a transcript of this conference call produced for The Motley Fool. While we strive for our Foolish Best, there may be errors, omissions, or inaccuracies in this transcript. Parts of this article were created using Large Language Models (LLMs) based on The Motley Fool's insights and investing approach. It has been reviewed by our AI quality control systems. Since LLMs cannot (currently) own stocks, it has no positions in any of the stocks mentioned. As with all our articles, The Motley Fool does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to the call yourself and reading the company's SEC filings. Please see our Terms and Conditions for additional details, including our Obligatory Capitalized Disclaimers of Liability.

The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.